Mark Ferguson
Chyle leak remains a challenging postoperative complication to manage, and avoidance is always easier than mitigation. The only predisposing factor identified in this study was low BMI. Although ICU stay was longer in affected patients,...
This study used lung cancer screening trial low dose CT scans to develop a model (Sybil) that predicts the likelihood of development of a lung cancer within the next year....
In a study meant to review outcomes in patients less than 5 kg supported by the Berlin Heart pulsatile ventricular assist device (VAD), it was found that the device is...
Transcatheter pulmonary valve replacement (TPVR) carries an increased risk of infective endocarditis. This study used data from the Pediatric Health Information System for the period 2010–2020. Ninety-eight hospital admissions for...
This 10-year follow-up of the ROBY study reports on the primary end points of all-cause death and the composite of death or revascularization among 2203 patients randomized to off-pump or...
This cautionary article outlines new trends in how the courts view surgeon responsibility for obtaining informed consent.
...This provocative editorial outlines concepts that thoracic surgeons should understand in the era of immunotherapy for potentially resectable N2 disease.
...This is an instructive editorial that reminds us of the challenges women face in CT surgery. It describes how to go beyond the social online movement to achieve practical changes...
In an announcement entitled “Retraction—Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study,” the results of an investigation by the Karolinska Institute were shared with The Lancet, resulting in...
This retrospective study of 328 patients undergoing resection for non-small cell lung cancer demonstrated that sarcopenia determined by psoas muscle mass on computed tomography was associated with increased postoperative complications...
This randomized trial evaluating the relative efficacy of immunotherapy and chemotherapy in patients with recurrent or metastatic disease, immunotherapy was associated with significantly better progression-free survival. Tumor mutational burden was...
The addition of pembrolizumab (targeting PD-1) to standard chemotherapy substantially improved time to progression and overall survival compared to chemotherapy alone in patients with metastatic lung cancer.
...Over 1200 patients with stable coronary artery disease and at least one angiographically-significant stenosis were randomized to percutaneous coronary intervention (PCI) plus medical therapy or medical therapy alone for lesions...

